IBOV 185,229.17 ▼ 0.41% IPSA 11,381.18 ▲ 1.30% IPC MEX 63,375.93 ▼ 0.78% MERVAL 3,021,926 ▼ 1.29% COLCAP 2,548.22 ▲ 1.05% BVL PERÚ 60,023.65 ▼ 1.13% USD/BRL5.14▲ 0.26% USD/MXN17.22▼ 0.01% USD/CLP959.00▼ 0.31% USD/COP3,175▲ 1.37% USD/PEN3.37▼ 0.10% USD/ARS1,514▲ 0.26% USD/UYU40.16▲ 2.90% USD/PYG5,906▲ 2.95% USD/BOB9.95▼ 6.56% USD/DOP58.83▲ 0.22% USD/CRC444.45▲ 2.49% USD/GTQ7.63▲ 3.03% USD/HNL26.85▲ 0.38% USD/NIO36.62▲ 2.64% USD/VES846.42▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.75▲ 2.57% EUR/BRL5.91▲ 0.04% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 185,229.17 ▼ 0.41% IPSA 11,381.18 ▲ 1.30% IPC MEX 63,375.93 ▼ 0.78% MERVAL 3,021,926 ▼ 1.29% COLCAP 2,548.22 ▲ 1.05% BVL PERÚ 60,023.65 ▼ 1.13% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, September 20, 2026

Neuralink’s Breakthrough in Brain Technology

By · January 30, 2024 · 2 min read

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Bolivia's 83% fuel shock, hours after the IMF loan”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Neuralink, co-founded by Elon Musk, achieved a pivotal milestone by successfully implanting the Telepathy device in a human brain.

This event, which took place on January 28, 2024, was announced by Musk the following day.

Telepathy allows users to control electronics, such as phones and computers, using just their thoughts.

Primarily targeting people with mobility impairments, it promises a revolutionary change in communication.

Musk envisions a future where individuals comparable to Stephen Hawking could communicate faster than skilled typists.

The patient with the Telepathy implant is showing encouraging progress, with early results indicating positive neuronal activity.

Details about the patient and the specific nature of the procedure, however, remain under wraps.

Neuralink's Breakthrough in Brain Technology
Neuralink’s Breakthrough in Brain Technology.
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

Neuralink received FDA approval for human brain chip trials in the previous year.

The company’s website now invites interested parties to join these clinical trials.

The study involves inserting a discreet implant into the brain area responsible for movement planning.

This advancement represents a major leap forward in brain-computer interface technology.

It has the potential to transform the lives of those with mobility challenges, offering new pathways for interaction and independence.

This successful implantation not only shows technological progress but also opens the door to future applications in various sectors.

Yet, this innovation carries substantial risks. Privacy and security are major concerns, with the integration of technology and the brain potentially exposing thoughts to unauthorized access.

Ethical questions about the balance between therapeutic use and enhancement also arise, potentially leading to social disparities.

The long-term effects of brain implants remain uncertain, and technical failures pose significant health risks.

Despite the promising benefits, careful consideration of ethical, privacy, and health implications is crucial.

Responsible development is key to ensuring the technology is used safely and effectively beneficial use.

This article was drafted with automated assistance and reviewed before publication. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map
FDA

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.